DNM1L and non-small cell lung carcinoma: Furthermore, luteolin treatment alone or in combination with TRAIL increased the phosphorylation of c-Jun N-terminal kinase (JNK), while SP600125 (the JNK inhibitor) significantly abolished the synergistic effect on DR5 expression and Drp1 translocation, indicating that the activation of JNK signaling was closely associated with the synergistic effect exerted by luteolin in NSCLC cells [49].